Abstract
In regions of high malaria transmission, mosquitoes repeatedly transmit liver-tropic Plasmodium sporozoites into individuals who already have blood-stage parasitaemia1. This manifests itself in older semi-immune children by concurrent carriage of different parasite genotypes at low asymptomatic parasitaemias2. Superinfection presents an increased risk of hyperparasitaemia and death in less immune individuals, but counter-intuitively is not frequently observed in the young3,4. Here, we show in a rodent model, that ongoing blood-stage infections, above a minimum threshold, impair the growth of subsequently inoculated sporozoites such that they become growth arrested in liver hepatocytes and fail to develop into blood-stage parasites. Inhibition of the liver-stage can be mediated by the host iron regulatory hormone hepcidin5, the synthesis of which is stimulated by blood-stage parasites in a density-dependent manner. We model this phenomenon and show how density-dependent protection against liver-stage malaria can shape the epidemiological patterns of age-related risk and complexity of malaria infections seen in young children. The interaction between these two Plasmodium stages and host iron metabolism has relevance for the global efforts to reduce malaria transmission and for nutritional programmes of iron supplementation in malaria-endemic regions.
An infected mosquito bite transmits Plasmodium sporozoites that infect hepatocytes producing thousands of merozoites6, that then infect red blood cells (RBCs) causing malaria7. In areas where malaria is endemic, individuals can be exposed to several hundred infected mosquito bites per year1, conferring a risk of superinfection. In infants yet to acquire immunity and whose passively transferred maternal immunity has waned, individual infections result in potentially life-threatening episodes of disease3. Superinfections would be expected to elevate this risk (as different parasites may multiply independently causing lethal parasitaemias) but only if the sporozoites of a superinfection progressed as normal through the liver-stage in individuals that already have ongoing blood parasitaemia.
To address this question we utilised a rodent model of malaria where luciferase- and GFP-tagged parasites enable distinction between the original infection and the superinfection. We infected mice via mosquito bite with P. berghei parasites and after detecting parasites in the bloodstream (peripheral blood parasitemia 0.99±0.03%), we challenged the same mice by mosquito bite with luciferase-expressing P. berghei. Light emission correlates with Plasmodium liver load8. Liver-stage infection was dramatically inhibited in mice with ongoing blood-stage parasitaemia (Fig. 1a). The observed reduction in secondary Plasmodium liver infection depended on the ongoing blood-stage infection, as mice first infected with blood-stage parasites via blood transfusion, and later challenged via mosquito bite with luciferase-expressing P. berghei displayed a similar impairment in liver infection (Fig. 1b). Most strikingly, luciferase-labelled parasites never reached detectable levels in the blood (Fig. 1c). A potent and significant reduction in P. berghei liver load was confirmed and quantified in mice with an ongoing blood-stage infection and challenged with sporozoites constitutively expressing GFP (Fig. 1d); qRT-PCR of GFP mRNA was used as readout as GFP expression correlates with Plasmodium liver load (Supplementary Fig. 1). Again, GFP-expressing parasites were never detected in blood (Fig. 1e). This effect was neither species- nor strain-specific. Mice carrying blood-stage infections with P. berghei NK65, P. berghei ANKA, P. chabaudi chabaudi AS or P. yoelii 17X parasites and challenged with GFP-expressing P. berghei ANKA sporozoites showed a very strong reduction in liver-stage infection (P<0.01; Fig. 1d). Likewise, P. berghei NK65 blood-stage infection strongly inhibited liver-stage infection by GFP-expressing P. yoelii 17X sporozoites (P<0.05; Fig. 1f).
The decrease in liver parasite load was consistently observed from day 3 to day 14 of a blood-stage malaria infection started with 106 iRBCs, when parasitaemia remained above 1% (1.24±0.24 – 15.53±3.80%; P<0.05; Fig. 1g). Additionally, when blood-stage parasitaemia was initiated with increasing numbers of iRBCs (103–107 iRBCs) but all re-infected with P. berghei ANKA sporozoites on day 3, we observed significant impairment in liver-stage infection at parasitemias exceeding 0.15% (0.16±0.07 – 3.61±0.63%; P<0.01) (induced following inoculation of 105 iRBCs) (P<0.05; Fig. 1h). Conversely, if an ongoing blood-stage infection was treated with the antimalarial drug chloroquine or naturally cleared from circulation (as during P. c. chabaudi AS infections) then inhibition of liver-stage development was abrogated (Fig. 1i, j). These data suggest that the observed decrease in liver parasite only occurs above a certain critical threshold of blood parasite density.
We next investigated the nature of the inhibition of Plasmodium liver-stage by an ongoing blood-stage infection. Microscopic examination of thick liver sections from control and reinfected mice from 3 independent experiments clearly revealed that both the number and size of exo-erythrocytic forms (EEFs) decrease in the presence of blood-stage parasites when measured 40 to 48h after sporozoite inoculation (Fig. 2a–d and Supplementary Fig. 1). Together these reductions account for the overall impairment to liver-stage development and mimic the observed reduction in infection liver load quantified by qRT-PCR in the same livers (Fig. 2d). No EEFs were detectable 72h after sporozoite infection in mice with a blood-stage infection (Supplementary Fig. 1).
Altogether, these data indicate that inhibition of Plasmodium liver infection by an ongoing malaria blood-stage infection is independent of the Plasmodium species, transient, and results in small EEFs that fail to generate detectable blood-stage infections. The data are also consistent with a critical density threshold of blood-stage parasites inhibiting the development of the liver-stage, resembling a quorum sensing mechanism described for bacteria9, by which the blood-stage is able to protect its niche from the threat of superinfection. We ruled out the possibility that a blood-stage secreted soluble factor was directly responsible for mediating inhibition since infection of both mouse primary hepatocytes and hepatoma cells by P. berghei sporozoites was unaffected by co-culture with iRBCs (Fig. 2e and Supplementary Fig. 2).
We next examined differences in host liver transcription between naïve mice (NI), sporozoite-infected mice (LS), mice carrying a blood-stage infection alone (BS) or after secondary sporozoite infection (Reinf) by genome-wide microarray analysis. Immune-related genes were upregulated in both BS and Reinf mice, and genes associated with a defense response, including several TLRs, chemokines, complement components or IFN regulatory factors were upregulated in the latter (Fig. 2f, Supplementary Fig. 3, and Supplementary Table 1), suggesting that a blood-stage initiated immune response might account for impaired liver-stage development. However, using either splenectomised mice, genetically deficient mice or depletion methods, we showed that the impairment of Plasmodium liver infection in the presence of blood-stage parasitaemia is independent of T or B cells; NK or γδ T cells; IFN-gamma, TNF-α, NOS, IL-10, IL-6, TLR/MyD88 signalling; the complement system or mastocytes (Fig. 2g–i and Supplementary Fig. 3). Lack of any of these independent components, or the administration of a general anti-inflammatory molecule (N-acetyl-cysteine) (Supplementary Fig. 3), did not even partially rescue the observed impairment. Moreover, luciferase-labelled parasites never reached detectable levels in the blood of immuno-depressed (SCID) re-infected mice. These data provide no support for a role of adaptive immunity or aspects of innate immunity in the phenotype observed. (Supplementary Fig. 3).
Plasmodium blood-stages increase apoptosis in hepatocytes10 and microarray data shows a robust pro-apoptotic stimulus in the livers of mice with an ongoing blood-stage infection (Supplementary Table 1). However, although a significantly reduced level of apoptosis was observed in P. berghei NK65 blood-stage infected caspase-3 deficient mice (Supplementary Fig. 4), blood-stage infection in these mice still impaired a secondary P. berghei ANKA liver infection (P<0.05; Fig. 2j). Thus, hepatocyte apoptosis does not explain the observed protection.
The reduction of both the number and size of EEF in the presence of a blood infection (Fig. 2a–c) suggested that some nutrient or growth factor might be limiting liver-stage development. Previous reports link iron availability and Plasmodium infection of both RBCs11 and hepatocytes12–14. hamp1, the gene encoding the iron regulatory hormone hepcidin, is significantly over-expressed in the livers of mice with ongoing blood-stage infection (2.7-fold increase in Reinf by microarray analysis, P<0.05, Supplementary Table 1). We confirmed by qRT-PCR an average 5-fold increase in hamp1 expression levels in mice with an ongoing blood-stage infection (P<0.01; Fig. 3a), consistent with previous findings of increased hepcidin in human blood-stage infection15,16. Importantly, hepcidin levels fully correlated with parasitemia and, above a certain threshold (3.3-fold hepcidin increase for 0.15% parasitemia), inversely correlated with Plasmodium liver infection (P<0.01; Fig. 3a). The increase in hepcidin mRNA depends on blood-stage parasitemia as it reverted to normal levels after chloroquine-treatment of infected mice (Fig. 3b) or after resolution of P. c. chabaudi AS infection (Supplementary Fig. 5), correlating with regained permissiveness to liver-stage re-infection (Fig. 1i, j). Hepcidin regulates iron homeostasis and distribution by targeting the iron exporter ferroportin for degradation, thereby preventing release of recycled RBC iron and dietary iron to serum from ferroportin-expressing macrophages and enterocytes respectively5,17. We showed that increased hamp1 expression during blood-stage infection was associated with iron redistribution: increased levels of ferritin within liver macrophages (Fig. 3c), increased iron in the spleen and reduced iron in hepatocytes (Fig. 3d). IL-6 and bone-morphogenetic proteins (BMPs) are known hepcidin agonists18,19. Blood-stage infection increased expression of Id1 (Supplementary Fig. 5), a known BMP target gene20 and hamp1 upregulation in primary hepatocytes by sera of blood-stage infected mice was inhibited by dorsomorphin (Fig 3e), a BMP signaling antagonist21. Induction was also partially neutralized by anti-IL-6 antibodies (Fig 3e), suggesting that BMP and IL-6 pathways may synergize to induce hepcidin during a blood-stage infection.
Previous microarray analysis showed that ferroportin expression was significantly reduced in Plasmodium-infected hepatoma cells (47.0±0.2% reduction, P<0.0001), and the iron importer DMT1 was significantly increased (2.0±0.2 fold increase, P<0.0001)22. This suggests that iron acquisition and retention might be essential for complete Plasmodium development inside its host cells. Consistent with this, reducing iron availability in liver-derived cells using iron chelators bathophenanthrolinedisulfonate (BPS) and desferrioxamine (DFO) led to significant and dose-dependent inhibition of Plasmodium EEF development (Fig. 3f–h and Supplementary Fig. 5) whereas iron supplementation using Ferric Ammonium Citrate (FAC) dramatically increased development (Fig. 3g, h). These effects were reproduced in mice infected with P. berghei sporozoites (Fig. 3h).
Our data reveal that iron, necessary for complete Plasmodium sporozoite development, is significantly reduced in hepatocytes during a malaria blood-stage infection, presumably due to increased hepcidin expression. Thus, elevated hepcidin alone without ongoing blood-stage infection should inhibit Plasmodium liver infection. Accordingly, administration of hepcidin peptide17,23,24 prior to and after sporozoite infection significantly impaired liver infection (Fig. 3i). Additionally, two distinct hepcidin over-expression systems (hamp1-expressing adenovirus-infected mice and hamp1-transgenic mice25, both causing a 2-fold increase in hamp1 expression) showed that hepcidin significantly reduces liver-stage infection (Fig. 3i) to levels similar to those observed during blood-stage infections (Fig. 3a). Altogether, these data are consistent with an ongoing blood-stage infection stimulating hepcidin expression and consequently redistributing iron away from hepatocytes where it is required for successful Plasmodium EEF development (Fig. 3j).
We next asked what implications our observations in mice might have for human malaria, assuming the same phenomenon operates. Epidemiological studies from highly endemic areas consistently show that the incidence of infection first increases with age in young children before declining as a result of acquired immunity (e.g.4,26). In parallel, the complexity of infection, i.e. the average number of parasite clones per individual, also increases as hosts get older4,26–28, so that older children frequently harbour asymptomatic infections consisting of multiple parasite genotypes2, whereas superinfection is rarely encountered in infants, even though these individuals are less immune. To investigate if a threshold-density dependent inhibitory effect, such as we report here, could account for these counter-intuitive observations we devised a simple agent-based model. We simulated infection histories in a number of individuals, following them over time whilst recording the average annual infection rates and number of co-infecting clones (see Supplementary Information). According to epidemiological observations, the model assumes that the average parasite density per infection decreases with age4, 27, 29. The probability of an infectious bite initiating a new infection then depends on current blood-stage parasitemia together with the host’s infection history. Under these minimal assumptions the model correctly predicts an initial increase in infection rates, which subsequently declines as individuals acquire immune protection through repeated exposure (Fig. 4a, c). We also observe an increase in the multiplicity of infection in older individuals as a consequence of higher infection risk and reduced inhibitory effect (Fig. 4b, d). We tested the model under various assumptions regarding the relationship between an ongoing blood-stage infection and the probability of superinfection and find that no other inhibitory effect can explain the observed data (Fig. 4a, b). The predictions of the model are also invariant to assumptions regarding age-dependent parasite clearance rates and maternal protection (Supplementary Fig. 6). This means that threshold-density dependent inhibition of new liver-stage infections alone can explain the changes in infection risk and complexity of infections in young individuals observed in the field. Crucially, however, our results show that this effect is strongly dependent on the transmission intensity and most prominently observed under moderate to high transmission settings (Fig. 4c and d). A previous attempt to explain these epidemiological observations30 relied on the biting preference of mosquitoes towards older individuals. Our findings provide an alternative (or synergistic) mechanism underlying the differences in age-dependent risk of infection within the endemicity spectrum (Fig. 4f).
Host/pathogen/environment interactions can be extremely complex. For example, in order to maximize survival, some bacteria employ quorum-sensing31, paracrine signalling32 and even hormonal communication with their host (called inter-kingdom signalling33). Similarly the intricacy of the Plasmodium life-cycle and its infection dynamics within host populations likely reflect behaviours that have been selected during co-evolution. Our results suggest a previously unsuspected aspect of this relationship, that blood-stage Plasmodium infections protect their erythrocyte niche from superinfection via the upregulation of a host hormone, hepcidin, which redistributes iron away from competitor liver-stage infections. This interaction acts independently of and in addition to acquired immunity and could resolve features of malaria epidemiology that have hitherto required speculative explanations (Fig 4f). It is possible that the mechanism we describe arose in order to maintain parasite density below life-threatening levels in non-immune individuals – benefitting both the host and the incumbent pathogen. The effect implies a balance of host iron levels, blood parasitaemia and the hepcidin response. One might therefore expect that altering iron availability could disturb these interactions. Indeed, a clinical trial of iron supplementation of under fives on Pemba island, Tanzania, where malaria is highly endemic, showed a statistically significant increase in malaria infections and risk of death in infants receiving iron34. Similarly, the profound and poorly explained anaemia that accompanies the disease may be partly due to the hepcidin response. Understanding how the life-stages of Plasmodium interact with the nutritional and immunological states of hosts of various ages may well benefit the current efforts to control malaria.
METHODS
Mice
Mice were bred in specific pathogen-free facilities at the Instituto de Gulbenkian de Ciência (Oeiras, Portugal). Rag2/gc deficient mice were kindly provided by James Di Santo (Institut Pasteur, Paris, France). Nos2- (B6.129P2-Nos2tm1Lau/J), Tcrd- (B6.129P2-Tcrdtm1Mom/J), and C5a- (B10.D2-Hc0.H2d.H2-T18c/oSnJ) deficient mice were purchased at The Jackson Laboratory along with respective wild type littermates. Mice were housed in the Instituto de Medicina Molecular (IMM) facilities and the IMM Animal Care Committee approved all protocols. Ifng deficient mice were kindly provided by Rui Appelberg (Instituto de Biologia Molecular e Celular-IBMC, Porto, Portugal) and experiments performed at IBMC after IBMC Animal Care Committee approved all protocols. All transgenic mice were genotyped by tail genomic DNA PCR to confirm their respective mutations.
Plasmodium blood infection
Primary blood-stage infection of mice was achieved by exposing mice for 30 minutes to 15 Anopheles mosquitoes infected with P. berghei ANKA, or by i.p. inoculation of the designated quantity of RBCs infected with P. berghei ANKA, P. berghei NK65, P. yoelii 17X NL or P. chabaudi chabaudi AS. Peripheral blood parasitaemia was determined by Giemsa staining followed by microscopic counting of iRBCs, real time in vivo imaging using the in vivo IVIS® Lumina Imaging System 8 (Fig. 1C) or flow cytometry of gfp-expressing parasites35 (Fig. 1E). The results are expressed as percentage of infected RBCs.
Plasmodium liver infection
gfp-expressing or luciferase-expressing P. berghei ANKA and gfp-expressing P. yoelii sporozoites8,35,36 were obtained by dissection of Anopheles stephensi infected mosquitoes bred at the IMM insectarium. Mice were infected i.v. with the designated quantity of sporozoites, or by 30 minutes exposure of mice to 15 infected Anopheles mosquitoes. Parasite liver load was quantified either by qRT-PCR or real time in vivo imaging using the in vivo IVIS® Lumina Imaging System8.
Liver slice histopathology, morphometric analysis and immunofluorescence
Livers were harvested from control or re-infected mice 40 h after sporozoite infection, fixed in 4% paraformaldehyde for 15 minutes, washed and then sliced into 50 μm sections using a vibratome (VT1000S, Leica). Sections were permeabilized and blocked overnight in 0.3% Triton X-100 + 1% BSA and then incubated overnight at 4°C in the same solution containing anti-GFP IgG Alexa flour 488 congugate antibody, Alexa 594 phaloidin and 4′,6-diamidino-2-phenylindole (DAPI). After mounting 20 sections on slides, EEFs were counted on a Leica DM5000B Widefield Fluorescence Microscope, and the sizes of 20 randomly chosen EEFs per mouse were measured using a Zeiss LSM 510 META Point Scanning Confocal Microscope. Images of immunofluorescence-stained sections were analysed using the ImageJ 1.42b software. Areas and numbers of EEF were normalized to the total area observed.
Liver hepcidin (hamp1) quantification
Liver hamp1 mRNA expression was determined by TaqMan qRT-PCR using inventoried TaqMan gene expression assays (hamp1 - Mm00519025_m1; gapdh (Glyceraldehyde-3-phosphate dehydrogenase) - Mm99999915_g1) and TaqMan Gene Expression Master Mix (both Applied Biosystems) according to the manufacturer’s instructions. qRT-PCR was performed using an ABI Prism 7500FAST system. Changes in hepcidin mRNA expression between control and re-infected mouse livers were calculated using the 2−DDCt method with gapdh as the endogenous control gene.
Ferritin staining
Livers sections, prepared and fixed as described above, were incubated overnight at 4°C with rabbit anti-mouse heavy and light ferritin chain antibody (a kind gift by Paolo Arosio, Faculty of Medicine, Brescia, Italy) and Alexa 660 phaloidin (Invitrogen). After washing, sections were incubated for 6h with secondary Alexa fluor 595 donkey anti-rat IgG (Invitrogen) and DAPI (Sigma).
Iron treatments
Huh7 cells were incubated with Ferric Ammonium Citrate (FAC, Sigma) bathophenanthrolinedisulfonate (BPS, Acros) or Desferrioxamine (DFO, Sigma) solutions at designated concentrations (or diluents as control) 24h prior to sporozoite infection and infection measured by FACS 36h after infection. For in vivo experiments, mice were inoculated i.p. with 250 mg/Kg of DFO or FAC 24h prior to sporozoite infection and parasite liver load measured 40h after infection.
Hepcidin induction
Hepcidin induction was achieved by (i) direct administration of hamp1 peptide (Peptide, Japan) 20h prior to sporozoite infection and 20h after sporozoite infection, (ii) hamp1-expressing adenoviral administration (pAd.CMV.Hamp.ires.GFP.Wpre (HAMP.adV) kindly provided by Stefano Rivella, Weill Cornell Medical College, USA) 48h prior to sporozoite infection or (iii) expression of human hamp1 transgene in mice25. Livers were collected 40 h after infection and parasite liver load determined by expression of PbA 18S rRNA.
Model description
A stochastic, individual-based model was used to follow a cohort of N individuals for up to 20 years in low, medium and high transmission settings (with according annual EIR of 2, 20 and 200, respectively). At each time point ti the probability of an individual becoming infected, P, is given as the product of the probability of being bitten by an infected mosquito, pbite (=1-1/EIR), times the probability of this bite leading to successful blood-stage infection which itself is dependent on the immune history of the host, pimm, and the parasite density of a possible ongoing infection, pdens. That is, P(infection) = P(pbite ∩ pimm ∩ pdens). More detailed model description in Supplementary Information online.
Statistical analysis
All experiments were performed with at least 5 mice per group. Displayed results are either one representative of or the cumulative result of at least three independent experiments. Statistical analysis was performed using unpaired Student t or variance (ANOVA) parametric tests; normal distributions were confirmed using the Kolmogorov-Smirnov test. Significance is indicated by * and its value is identified in every graph.
Supplementary Material
Acknowledgments
We would like to thank Laurent Renia (Agency for Science, Technology and Research, Singapore) for helpful comments and reagents, as well as Rui Appelberg (Instituto de Biologia Molecular e Celular, Porto, Portugal), James Di Santo (Institut Pasteur, Paris, France) and Juan Rivera (National Institutes of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, USA) for IFN-γ, RAG2/γc and Kit W-sh transgenic mice, Stefano Rivella (Weill Cornell Medical College, New York, USA) for GFP and HAMP.GFP-expressing adenovirus, and Paolo Arosio, (Faculty of Medicine University of Brescia, Italy) for anti-mouse heavy and light ferritin chain antibody.
This work was supported by Fundação para a Ciência e Tecnologia (FCT, Portugal), European Science Foundation (EURYI to MMM), Howard Hughes Medical Institute and the Medical Research Council UK. H.D. is a Beit Memorial Fellow for Medical Research and an MRC New Investigator. S.P. and C.C. were supported by FCT fellowships (SFRH/BD/31523/2006 and SFRH/BPD/40965/2007 respectively). M.R. is supported by a Royal Society University Research Fellowship.
Footnotes
Note: Supplementary information, including full methods, is available on the Nature Medicine website.
AUTHOR CONTRIBUTIONS
S.P. performed the majority of the experimental work. C.C. performed the microarray analysis and M.R. and C.N. initiated and tested the mathematical model. L.A.G. produced murine primary hepatocytes. S.E., D.S. and C.R. provided intellectual input and C.R. provided hamp1-transgenic mice. M.M.M. has conceived and supervised the study. S.P., A.A., C.N., H.D. and M.M.M. designed the experimental procedures and wrote the manuscript. All authors read and approved the manuscript.
References and Notes
- 1.Robert V, et al. Malaria transmission in urban sub-Saharan Africa. Am J Trop Med Hyg. 2003;68:169–176. [PubMed] [Google Scholar]
- 2.al-Yaman F, et al. Reduced risk of clinical malaria in children infected with multiple clones of Plasmodium falciparum in a highly endemic area: a prospective community study. Trans R Soc Trop Med Hyg. 1997;91:602–605. doi: 10.1016/s0035-9203(97)90046-8. [DOI] [PubMed] [Google Scholar]
- 3.Smith TA, Leuenberger R, Lengeler C. Child mortality and malaria transmission intensity in Africa. Trends Parasitol. 2001;17:145–149. doi: 10.1016/s1471-4922(00)01814-6. [DOI] [PubMed] [Google Scholar]
- 4.Molineaux L, Gramiccia G. The Garki project: research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. World Health Organization; Geneva: 1980. [Google Scholar]
- 5.Ganz T. Hepcidin--a peptide hormone at the interface of innate immunity and iron metabolism. Curr Top Microbiol Immunol. 2006;306:183–198. doi: 10.1007/3-540-29916-5_7. [DOI] [PubMed] [Google Scholar]
- 6.Prudencio M, Rodriguez A, Mota MM. The silent path to thousands of merozoites: the Plasmodium liver stage. Nat Rev Microbiol. 2006;4:849–856. doi: 10.1038/nrmicro1529. [DOI] [PubMed] [Google Scholar]
- 7.Haldar K, Murphy SC, Milner DA, Taylor TE. Malaria: mechanisms of erythrocytic infection and pathological correlates of severe disease. Annual review of pathology. 2007;2:217–249. doi: 10.1146/annurev.pathol.2.010506.091913. [DOI] [PubMed] [Google Scholar]
- 8.Ploemen IH, et al. Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging. PLoS One. 2009;4:e7881. doi: 10.1371/journal.pone.0007881. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Henke JM, Bassler BL. Bacterial social engagements. Trends Cell Biol. 2004;14:648–656. doi: 10.1016/j.tcb.2004.09.012. [DOI] [PubMed] [Google Scholar]
- 10.Guha M, Kumar S, Choubey V, Maity P, Bandyopadhyay U. Apoptosis in liver during malaria: role of oxidative stress and implication of mitochondrial pathway. Faseb J. 2006;20:1224–1226. doi: 10.1096/fj.05-5338fje. [DOI] [PubMed] [Google Scholar]
- 11.Heppner DG, Hallaway PE, Kontoghiorghes GJ, Eaton JW. Antimalarial properties of orally active iron chelators. Blood. 1988;72:358–361. [PubMed] [Google Scholar]
- 12.Goma J, Renia L, Miltgen F, Mazier D. Effects of iron deficiency on the hepatic development of Plasmodium yoelii. Parasite. 1995;2:351–356. [PubMed] [Google Scholar]
- 13.Goma J, Renia L, Miltgen F, Mazier D. Iron overload increases hepatic development of Plasmodium yoelii in mice. Parasitology. 1996;112 (Pt 2):165–168. doi: 10.1017/s0031182000084729. [DOI] [PubMed] [Google Scholar]
- 14.Stahel E, et al. Iron chelators: in vitro inhibitory effect on the liver stage of rodent and human malaria. Am J Trop Med Hyg. 1988;39:236–240. doi: 10.4269/ajtmh.1988.39.236. [DOI] [PubMed] [Google Scholar]
- 15.Armitage AE, Pinches R, Eddowes LA, Newbold CI, Drakesmith H. Plasmodium falciparum infected erythrocytes induce hepcidin (HAMP) mRNA synthesis by peripheral blood mononuclear cells. Br J Haematol. 2009 doi: 10.1111/j.1365-2141.2009.07880.x. [DOI] [PubMed] [Google Scholar]
- 16.de Mast Q, et al. Assessment of urinary concentrations of hepcidin provides novel insight into disturbances in iron homeostasis during malarial infection. J Infect Dis. 2009;199:253–262. doi: 10.1086/595790. [DOI] [PubMed] [Google Scholar]
- 17.Nemeth E, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–2093. doi: 10.1126/science.1104742. [DOI] [PubMed] [Google Scholar]
- 18.Babitt JL, et al. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007;117:1933–1939. doi: 10.1172/JCI31342. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Nemeth E, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101:2461–2463. doi: 10.1182/blood-2002-10-3235. [DOI] [PubMed] [Google Scholar]
- 20.Katagiri T, et al. Identification of a BMP-responsive element in Id1, the gene for inhibition of myogenesis. Genes Cells. 2002;7:949–960. doi: 10.1046/j.1365-2443.2002.00573.x. [DOI] [PubMed] [Google Scholar]
- 21.Yu PB, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2008;4:33–41. doi: 10.1038/nchembio.2007.54. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Albuquerque SS, et al. Host cell transcriptional profiling during malaria liver stage infection reveals a coordinated and sequential set of biological events. BMC Genomics. 2009;10:270. doi: 10.1186/1471-2164-10-270. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Drakesmith H, et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood. 2005;106:1092–1097. doi: 10.1182/blood-2005-02-0561. [DOI] [PubMed] [Google Scholar]
- 24.Rivera S, et al. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood. 2005;106:2196–2199. doi: 10.1182/blood-2005-04-1766. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Roy CN, et al. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood. 2007;109:4038–4044. doi: 10.1182/blood-2006-10-051755. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Sama W, Owusu-Agyei S, Felger I, Dietz K, Smith T. Age and seasonal variation in the transition rates and detectability of Plasmodium falciparum malaria. Parasitology. 2006;132:13–21. doi: 10.1017/S0031182005008607. [DOI] [PubMed] [Google Scholar]
- 27.Mayor A, et al. Plasmodium falciparum multiple infections in Mozambique, its relation to other malariological indices and to prospective risk of malaria morbidity. Trop Med Int Health. 2003;8:3–11. doi: 10.1046/j.1365-3156.2003.00968.x. [DOI] [PubMed] [Google Scholar]
- 28.Owusu-Agyei S, Smith T, Beck HP, Amenga-Etego L, Felger I. Molecular epidemiology of Plasmodium falciparum infections among asymptomatic inhabitants of a holoendemic malarious area in northern Ghana. Trop Med Int Health. 2002;7:421–428. doi: 10.1046/j.1365-3156.2002.00881.x. [DOI] [PubMed] [Google Scholar]
- 29.Mmbando BP, et al. Epidemiology of malaria in an area prepared for clinical trials in Korogwe, north-eastern Tanzania. Malar J. 2009;8:165. doi: 10.1186/1475-2875-8-165. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Smith T, et al. Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria. Am J Trop Med Hyg. 2006;75:11–18. doi: 10.4269/ajtmh.2006.75.2_suppl.0750011. [DOI] [PubMed] [Google Scholar]
- 31.Fuqua C, Winans SC, Greenberg EP. Census and consensus in bacterial ecosystems: the LuxR-LuxI family of quorum-sensing transcriptional regulators. Annu Rev Microbiol. 1996;50:727–751. doi: 10.1146/annurev.micro.50.1.727. [DOI] [PubMed] [Google Scholar]
- 32.Lopez D, Vlamakis H, Losick R, Kolter R. Paracrine signaling in a bacterium. Genes Dev. 2009;23:1631–1638. doi: 10.1101/gad.1813709. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Hughes DT, Sperandio V. Inter-kingdom signalling: communication between bacteria and their hosts. Nat Rev Microbiol. 2008;6:111–120. doi: 10.1038/nrmicro1836. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Sazawal S, et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. Lancet. 2006;367:133–143. doi: 10.1016/S0140-6736(06)67962-2. [DOI] [PubMed] [Google Scholar]
- 35.Franke-Fayard B, et al. A Plasmodium berghei reference line that constitutively expresses GFP at a high level throughout the complete life cycle. Mol Biochem Parasitol. 2004;137:23–33. doi: 10.1016/j.molbiopara.2004.04.007. [DOI] [PubMed] [Google Scholar]
- 36.Tarun AS, et al. Quantitative isolation and in vivo imaging of malaria parasite liver stages. Int J Parasitol. 2006;36:1283–1293. doi: 10.1016/j.ijpara.2006.06.009. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.